Who
Harlan Waksal
Other role
Company insider
Files Form 4 as: Other, Freenome; Executive Chair, Lyra Therapeutics; President, CEO, Kadmon Holdings; Director, Eloxx Pharmaceuticals.
In numbers
- Trades disclosed
- 82
- Buys
- 11
- Sells
- 0
- Bought
- $1.5M
- Sold
- $0
- Companies
- 4
- Companies where not an officer
- 2
- First trade
- 20 Feb 2009
- Last trade
- 20 Jul 2026
- Last filed
- 29 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 20 Jul 2026filed 29 Jul 2026 | FRNM FreenomeDiagnostics & Labs | SEC FORM 4 Code C | —30,000 | filing |
| 20 Jul 2026filed 29 Jul 2026 | FRNM Freenomeoption or derivative · Diagnostics & Labs | SEC FORM 4 Code C | —30,000 | filing |
| 20 Jul 2026filed 29 Jul 2026 | FRNM Freenomeoption or derivative · Diagnostics & Labs | SEC FORM 4 Code C | —30,000 | filing |
| 20 Jul 2026filed 29 Jul 2026 | FRNM FreenomeDiagnostics & Labs | SEC FORM 4 Code C | —30,000 | filing |
| 9 Dec 2024filed 11 Dec 2024 | Lyra Therapeuticsoption or derivative | SEC FORM 4 Code A | —128,333 at $0.00 | filing |
| 18 Mar 2024filed 20 Mar 2024 | Lyra Therapeutics | SEC FORM 4 Code A | —275,000 at $0.00 | filing |
| 10 Nov 2023filed 13 Nov 2023 | Lyra Therapeutics | SEC FORM 4 Bought | $74K25,000 at $2.96 | filing |
| 31 Jan 2023filed 2 Feb 2023 | Lyra Therapeuticsoption or derivative | SEC FORM 4 Code A | —200,000 at $0.00 | filing |
| 16 Jun 2022filed 21 Jun 2022 | Lyra Therapeuticsoption or derivative | SEC FORM 4 Code A | —953,002 at $0.00 | filing |
| 12 Apr 2022filed 13 Apr 2022 | Lyra Therapeutics | SEC FORM 4 Bought | $1000K236,966 at $4.22 | filing |
| 16 Feb 2022filed 18 Feb 2022 | Lyra Therapeuticsoption or derivative | SEC FORM 4 Code A | —520,000 at $0.00 | filing |
| 9 Nov 2021filed 9 Nov 2021 | Kadmon Holdingsoption or derivative | SEC FORM 4 Code D | $3.8M655,000 at $5.86 | filing |
| 9 Nov 2021filed 9 Nov 2021 | Kadmon Holdingsoption or derivative | SEC FORM 4 Code D | $5.3M982,500 at $5.44 | filing |
| 9 Nov 2021filed 9 Nov 2021 | Kadmon Holdingsoption or derivative | SEC FORM 4 Code D | $7.2M1,350,000 at $5.35 | filing |
| 9 Nov 2021filed 9 Nov 2021 | Kadmon Holdingsoption or derivative | SEC FORM 4 Code D | $11.1M2,000,000 at $5.54 | filing |
| 9 Nov 2021filed 9 Nov 2021 | Kadmon Holdingsoption or derivative | SEC FORM 4 Code D | $2,625750 at $3.50 | filing |
| 9 Nov 2021filed 9 Nov 2021 | Kadmon Holdings | SEC FORM 4 Code D | $1.7M177,945 at $9.50 | filing |
| 13 May 2021filed 17 May 2021 | Kadmon Holdings | SEC FORM 4 Code A | $89K25,000 at $3.56 | filing |
| 3 Apr 2021filed 6 Apr 2021 | Kadmon Holdingsoption or derivative | SEC FORM 4 Code A | —327,498 | filing |
| 8 Jan 2021filed 12 Jan 2021 | Kadmon Holdingsoption or derivative | SEC FORM 4 Code A | —2,000,000 at $0.00 | filing |
News
Eloxx Pharmaceuticals Finalizes 52-Week Phase 2 EXPRESS Study Design in Nonsense-Mutation ADPKD and Appoints T.R. Srinivas, M.D., Chief Medical OfficerELOX · prnewswire.com · 20 Oct 2026Eloxx Pharmaceuticals Appoints Biopharmaceutical Industry Veteran Geno Germano to its Board of DirectorsELOX · prnewswire.com · 19 Oct 2026Head to Head Review: Cumberland Pharmaceuticals (NASDAQ:CPIX) & Eloxx Pharmaceuticals (NASDAQ:ELOX)ELOX · dailypolitical.com · 17 Oct 2026
0 headlines in the last 90 days name Harlan Waksal; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.